Treatment of metastatic prostate cancer after STAMPEDE
Over decades, long-term hormone therapy has been considered as the standard of care (SOC) for men with advanced prostate cancer. The problem is that several months after the commencement of treatment, tumors become castration-resistant and virtually all patients show disease progression. In 2004, two randomized Phase 3 trials demonstrated a modest overall survival benefit of about 3 months with docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC) (1,2). This led to the use of docetaxel as first-line SOC in this stage of the disease.